NTRB
ニュートリバンド
Nutriband Inc.
通常取引データ（自動更新なし）RVOL 0.6xDV $14,14420日平均DV $22,118?
Earnings 2026-09-3052W high -61.7%52W low +17.9%Fwd PER 2.1xMarket cap $35MAvg volume 7K
Company Overview
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q1 | -0.10 | $433,399 | -$563,104 |
| 2026 Q4 | -0.08 | $400,709 | -$731,830 |
| 2025 Q3 | -0.32 | $346,058 | -$2M |
| 2025 Q2 | -2.12 | $622,452 | -$1M |
| 2025 Q1 | -0.12 | $667,432 | -$1M |
| 2025 Q4 | -0.51 | $642,379 | -$1M |
|
